Sientra, Inc. (NASDAQ:SIEN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “

A number of other analysts have also recently issued reports on the stock. Lake Street Capital reissued a “buy” rating and issued a $15.00 price objective (up from $11.00) on shares of Sientra in a research note on Tuesday, August 8th. Stephens began coverage on shares of Sientra in a research note on Tuesday, July 11th. They issued an “overweight” rating and a $12.00 price objective for the company. Finally, ValuEngine raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd.

Shares of Sientra (NASDAQ SIEN) opened at 10.39 on Tuesday. Sientra has a 52 week low of $6.92 and a 52 week high of $11.47. The stock’s market cap is $198.78 million. The stock’s 50 day moving average is $10.53 and its 200 day moving average is $9.00.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.04. The firm had revenue of $8.20 million during the quarter, compared to analysts’ expectations of $6.97 million. Sientra had a negative net margin of 173.83% and a negative return on equity of 52.30%. Sientra’s revenue for the quarter was up 32.3% on a year-over-year basis. On average, equities analysts forecast that Sientra will post ($3.07) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/17/sientra-inc-sien-stock-rating-lowered-by-zacks-investment-research.html.

A number of institutional investors have recently bought and sold shares of the stock. KCG Holdings Inc. bought a new position in Sientra during the first quarter valued at $147,000. Renaissance Technologies LLC bought a new position in Sientra during the first quarter valued at $224,000. Morgan Stanley boosted its position in Sientra by 449.6% in the first quarter. Morgan Stanley now owns 128,358 shares of the medical instruments supplier’s stock valued at $1,081,000 after buying an additional 105,005 shares during the last quarter. Cannell Capital LLC boosted its position in Sientra by 2.3% in the first quarter. Cannell Capital LLC now owns 1,139,571 shares of the medical instruments supplier’s stock valued at $9,595,000 after buying an additional 26,000 shares during the last quarter. Finally, Mission Wealth Management LLC bought a new position in Sientra during the first quarter valued at $104,000. 78.57% of the stock is owned by institutional investors.

Sientra Company Profile

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Receive News & Stock Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related stocks with our FREE daily email newsletter.